Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 30Thoracic 5Breast 3Plasma cell 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Breast Neoplasms 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Darbepoetin alfa × Other hematologic neoplasm × Clear all
NCT00036023 2009-05-11

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

Amgen

Phase 2 Completed
BreastLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡